CRDF (Cardiff Oncology) Cyclically Adjusted Revenue per Share: $0.27 (As of Mar. 2026)


CRDF Cardiff Oncology Inc CRDF
48 GF Score
Price $1.33
GF Value $1.42
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Cyclically Adjusted Revenue per Share?

Cardiff Oncology CRDF +0.76% 48 Cyclically Adjusted Revenue per Share is $0.27 as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 48/100 and a GF Value™ of $1.42 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cardiff Oncology's adjusted revenue per share for the three months ended in Mar. 2026 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.27 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Cardiff Oncology's average Cyclically Adjusted Revenue Growth Rate was -27.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -22.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cardiff Oncology was -20.60% per year. The lowest was -22.70% per year. And the median was -22.70% per year.

As of today (2026-07-11), Cardiff Oncology's current stock price is $1.325. Cardiff Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.27. Cardiff Oncology's Cyclically Adjusted PS Ratio of today is 4.91.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cardiff Oncology was 19.75. The lowest was 1.41. And the median was 5.86.


Cardiff Oncology  (NAS:CRDF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cardiff Oncology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.325/0.27
=4.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cardiff Oncology was 19.75. The lowest was 1.41. And the median was 5.86.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cardiff Oncology Cyclically Adjusted Revenue per Share Related Terms


Cardiff Oncology Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Cyclically Adjusted Revenue per Share Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.91 0.67 0.54 0.42 0.31

Cardiff Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.35 0.33 0.31 0.27

CRDF vs MAIA, TELO, OSTX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Cardiff Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Cyclically Adjusted PS Ratio falls into.


CRDF
48GF Score
Cardiff Oncology Inc CRDF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cardiff Oncology's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.001/330.2130*330.2130
=0.001

Current CPI (Mar. 2026) = 330.2130.

Cardiff Oncology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.248 241.018 0.340
201609 0.211 241.428 0.289
201612 0.159 241.432 0.217
201703 0.221 243.801 0.299
201706 0.237 244.955 0.319
201709 0.243 246.819 0.325
201712 0.331 246.524 0.443
201803 0.130 249.554 0.172
201806 0.091 251.989 0.119
201809 0.026 252.439 0.034
201812 0.020 251.233 0.026
201903 0.015 254.202 0.019
201906 0.007 256.143 0.009
201909 0.009 256.759 0.012
201912 0.011 256.974 0.014
202003 0.007 258.115 0.009
202006 0.003 257.797 0.004
202009 0.006 260.280 0.008
202012 0.003 260.474 0.004
202103 0.002 264.877 0.002
202106 0.002 271.696 0.002
202109 0.002 274.310 0.002
202112 0.003 278.802 0.004
202203 0.002 287.504 0.002
202206 0.002 296.311 0.002
202209 0.002 296.808 0.002
202212 0.003 296.797 0.003
202303 0.002 301.836 0.002
202306 0.002 305.109 0.002
202309 0.003 307.789 0.003
202312 0.003 306.746 0.003
202403 0.005 312.332 0.005
202406 0.004 314.175 0.004
202409 0.004 315.301 0.004
202412 0.003 315.605 0.003
202503 0.002 319.799 0.002
202506 0.002 322.561 0.002
202509 0.002 324.800 0.002
202512 0.004 324.054 0.004
202603 0.001 330.213 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.27 mean?
Cardiff Oncology (CRDF) has a Cyclically Adjusted Revenue per Share of $0.27 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's Cyclically Adjusted Revenue per Share too high?
Cardiff Oncology's current Cyclically Adjusted Revenue per Share is $0.27. Overall, Cardiff Oncology has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Cyclically Adjusted Revenue per Share compare to MAIA and TELO?
Cardiff Oncology's Cyclically Adjusted Revenue per Share of $0.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Cyclically Adjusted Revenue per Share is $0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Fairly Valued. The stock's GF Value™ is $1.42, compared to a current price of $1.33 — trading 6.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.27. Cardiff Oncology's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Cyclically Adjusted Revenue per Share is $0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.33 is trading 6.7% below its estimated GF Value™ of $1.42. GuruFocus considers Cardiff Oncology to be Fairly Valued.

Key valuation signals for CRDF:

  • Cyclically Adjusted Revenue per Share: $0.27
  • GF Value™: $1.42 vs. price of $1.33 (6.7% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
48GF Score

Get the complete analysis for CRDF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price
$1.42
GF Value